IRS2 and prostate carcinoma: To examine the impact of HIC1/AR/IRS2 on the progression of castration‐resistant prostate cancer, we injected HIC1‐silenced cells (LNCaP‐sh‐HIC1) and a control group (LNCaP‐sh‐NC) labeled with fluorescence into the posterior lobe of the prostate.